Canaccord Genuity Maintains Buy on Stoke Therapeutics, Raises Price Target to $60

Benzinga Newsdesk www.benzinga.com Positive 83.7%

Neg 0% Neu 0% Pos 83.7%

Canaccord Genuity analyst Sumant Kulkarni maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and raises the price target from $36 to $60.